Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07341048

Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia Vera

Polycythemia vera (PV) is a rare haematological disorder characterized by an excessive production of red blood cells, associated with the somatic JAK2 V617F mutation. Clinical manifestations are varied and often include exercise intolerance but the underlying mechanisms remain poorly understood.

Physical activity is recommended in the management of chronic diseases, but it must be tailored to the physiological profile of the patient. A cardiopulmonary exercise test (CPET) is essential to ensure safety, detect possible contraindications, and assess maximal oxygen uptake (VO₂max), a key indicator of aerobic performance.

This prospective, experimental, non-randomized study will include patients with PV followed at Lyon Sud University Hospital and for which a CPET is scheduled in their routine clinical follow-up. The primary objective is to compare VO₂max between two groups of patients: moderate (<10%) versus marked (≥10%) extent of blood viscosity increase after the completion of the CPET. The main hypothesis is that a significant increase in blood viscosity during exercise (≥10%) is a major limiting factor in oxygen transport and leads to a reduced VO₂max, reflecting impaired exercise tolerance.

Secondary analyses will focus on hemorheological parameters, tissue oxygenation, and cardiorespiratory and metabolic responses. The study aims to better understand the biological and physiological determinants of exercise intolerance in this population.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Polycythemia Bone Marrow Diseases Bone Marrow Neoplasms Hematologic Diseases Hematologic Neoplasms Hemic and Lymphatic Diseases Myeloproliferative Disorders Neoplasms Neoplasms by Site Polycythemia Vera Polycythemia Vera (PV)

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Sports Medicine and Physical Activity. Pulmonary Function Testing. Croix Rousse Hospital.

Lyon, 69001, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged at least 18 years and under 70.
  • Patient followed for a diagnosis of Polycytemia vera (confirmed JAK2 V617F mutation) and who were prescribed a CPET because of their wish to resume regular physical activity.
  • Patient affiliated with or benefiting from a social security scheme.

Exclusion criteria

  • Any known history of heart disease or chronic respiratory illness likely to affect VO₂max independently of Polycytemia vera (e.g., asthma), according to the investigator's judgment.
  • Any known history of major thromboembolic complication, according to the investigator's judgment.
  • Body mass index (BMI) greater than 35, according to the investigator's judgment.
  • Participation in another interventional research protocol that may interfere with the present study, according to the investigator's judgment.
  • Adult subject under legal protection measures (guardianship, curatorship).
  • Subject currently receiving psychiatric care.
  • Subject deprived of liberty by judicial or administrative decision.

Treatment and study plan

Research samples blood viscosity and viscoelasticity:

Biological

Research samples: Blood rheology: hematocrit, blood viscosity, deformability and erythrocyte aggregation, viscoelasticity

Other names: the level of tissue oxygenation and hemoglobin oxygenation that will be measured by near-infrared spectroscopy (NIRS).

Primary outcomes

  1. Blood viscosity (Centipoise) at 6 shear rates.

    Time frame: Measurements will be performed at baseline (pre-test), at 3 minutes post-CPET, and at 60 minutes post-CPET

    Blood viscosity will be measured using a cone-plate viscometer (Brookfield, model LVDVII+ PRO, cone CPE 40) on native hematocrit blood, at 7 different shear rates: 2.25, 4.5, 11.5, 22.5, 45, 90, and 225 s-¹, using an ascending ramp shear protocol.

Secondary outcomes

  1. Rheological properties of blood: deformability and aggregation of erythrocytes

    Time frame: Measurements will be performed at baseline (pre-test), at 3 minutes post-CPET, and at 60 minutes post-CPET.

    Analyses will be performed on EDTA tubes. Erythrocyte deformability will be measured by ektacytometry at 9 shear stresses (0.3-30 Pa) under isotonic conditions. Maximal elongation index (EImax) and shear stress for 50% deformation (SS₁/₂) will be recorded. Aggregation/disaggregation will be assessed by syllectometry at 40% hematocrit. Parameters include aggregation index (AI) and minimal shear rate (γmin) for full disaggregation

  2. Viscoelasticity of blood

    Time frame: Measurements will be performed at baseline (pre-test), at 3 minutes post-CPET, and at 60 minutes post-CPET

    Viscoelastic properties of blood will be assessed using rotational thromboelastometry (ROTEM delta) on citrated blood tubes. The following tests will be performed: NATEM, TEMACT, FIBTEM, and EXTEM. For each test, the following parameters will be measured: clotting time (CT, in seconds), clot amplitude at 5, 10, 20, and 30 minutes (A5, A10, A20, A30, in mm), alpha angle (indicating clot formation velocity, in degrees), maximum clot firmness (in mm), percentage of clot lysis at 30 minutes (LI30), as well as lysis onset time (LOT) and total lysis time (LT), both expressed in seconds

  3. Tissue and haemoglobin oxygenation with near-infrared spectroscopy (NIRS)

    Time frame: Measurement will be performed during the CPET.

    Near-infrared spectroscopy (NIRS) will be performed using the Portamon MKIII system (Artinis) with a sampling rate of 100 Hz. This non-invasive technique involves placing surface electrodes on the skin over the vastus lateralis muscle, halfway between the anterior superior iliac spine and the patella. NIRS enables continuous monitoring of changes in oxyhemoglobin (HbO₂) and deoxyhemoglobin (HHb) concentrations, allowing for the calculation of the tissue oxygenation index (TOI)

Interested in participating?

Not yet recruiting

Trial opening soon.

Get Notified

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Characterization of Exercise Intolerance in Patients With Polycythemia Vera: Study of Potential Biological and Physiological Determinants.

Acronym: ACTIVAQ

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 14, 2026
Registry last updated
Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.